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Abstract The relationship between protein kinase C (PKC)
activation and Ras function was investigated in cardiac cells. Ras
function was required for ERK activation by phorbol esters in
cardiac myocytes, but not in cardiac fibroblasts. Accordingly,
treatment with phorbol esters resulted in GTP loading of Ras in
cardiac myocytes, but not fibroblasts. Ras activation by phorbol
esters was abolished by a PKC specific inhibitor, but was
insensitive to tyrosine kinase inhibitors. Ras activation was
mediated by stimulation of guanine nucleotide exchange. These
results suggest the existence of a novel pathway for Ras
activation, specific to cardiac myocytes, with implications for
myocardial hypertrophy.
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1. Introduction
The small G-protein Ras plays a central role in signaling
pathways leading to hypertrophy of cardiac myocytes [1^4].
Among the pathways that are activated downstream of Ras,
the ERK1/2 MAP kinase pathway is one of the best under-
stood. The immediate downstream e¡ectors of Ras in this
pathway are the Raf kinases A-Raf, B-Raf and Raf-1. Raf
kinases can also be activated by phosphorylation by protein
kinase C (PKC). Although activation of Raf by PKC was
shown to be independent of Ras [5] in COS cells and
NIH3T3 ¢broblasts, experiments performed in PC12 pheo-
chromocytoma cells indicated that the activity of Ras was
required for Raf activation by PKC in this cell type [6,7]. In
addition, in COS cells, activation of PKC by phorbol esters
resulted in activation of Ras [8]. However, expression of dom-
inant-negative Ras did not inhibit Raf activation by PKC in
these cells. Thus, the relationship between Ras, Raf and PKCs
appears to be cell-type speci¢c.
In a recent study we observed activation of the glucose
transporter glut1 promoter by phorbol esters in two di¡erent
types of primary cardiac cells, i.e. myocytes and ¢broblasts
[9]. The two cell types exhibited a major di¡erence in that
activation of the glut1 promoter could be inhibited by domi-
nant-negative Ras in cardiac myocytes, but not in cardiac
¢broblasts. Moreover, we found that phorbol esters elicited
GTP loading of Ras in cardiac myocytes exclusively. In the
present study we further investigated the mechanisms by
which phorbol esters activate Ras in primary cardiac myo-
cytes.
2. Materials and methods
2.1. Cell culture
Primary ventricular myocytes were isolated from 1 day old rats by
collagenase digestion and maintained in Dulbecco’s modi¢ed Eagle’s
medium (DMEM)/medium 199 (4/1) supplemented with penicillin and
streptomycin (maintenance medium, MM) as previously described
[10]. Cytosine arabinoside was added at a ¢nal concentration of 10
WM to prevent growth of contaminating ¢broblasts (typically less than
5% of the cells). For ERK activation experiments, cells were plated at
a density of 2.5U105 per 3.5 cm dish. For activated Ras assay and
determination of guanine nucleotide exchange factor (GEF) activity,
2U106 cells were plated in 6 cm dishes.
Cardiac ¢broblast cultures were prepared by two passages of the
cells adherent to the culture dish during the preplating procedure.
Cells were maintained in MM supplemented with 10% fetal calf se-
rum. Con£uent 3.5 cm dishes were used for ERK1/2 activation assays
and con£uent 10 cm dishes were used for activated Ras assay.
2.2. ERK activation assay
Cells in 3.5 cm dishes were pretreated with or without lovastatin for
16 h, then treated with either tetradecanoyl phorbol acetate (TPA) or
its vehicle for 5 min. Cells were then harvested in 200 Wl RIPA bu¡er
and 90 Wg of proteins were subjected to SDS-PAGE and blotted onto
PVDF. Total ERKs and doubly phosphorylated (Thr-202/Tyr-204)
ERKs were detected by Western blotting using the K-23 rabbit poly-
clonal antibody (Santa Cruz) and the E10 monoclonal antibody (New
England Biolabs), respectively. Signals were quantitated using the
Lumi-Imager system with the LumiAnalyst software (Boehringer
Mannheim).
2.3. Activated Ras assay
The expression plasmid pGEX-RBD, encoding the Ras binding
domain of cRaf-1 fused to GST (GST-RBD) [11], was kindly donated
by Stephen J. Taylor. Detection of Ras-GTP in cell extracts was
performed as described [11]. Brie£y, cell lysates were incubated with
GST-RBD pre-bound to glutathione-Sepharose (Pharmacia) for 30
min at 4‡C. Bound proteins were eluted with SDS-PAGE sample
bu¡er, resolved on 12% polyacrylamide gels and subjected to Western
blotting. Blots were probed using an anti-H-Ras rabbit polyclonal
antibody (Santa Cruz sc-520). Aliquots (10%) of total cell lysate
were also resolved for quantitation of total Ras and determination
of ERK1/2 phosphorylation.
2.4. Determination of guanine exchange factor activity
GEF activity in myocytes and ¢broblasts was determined as pre-
viously described [12]. Brie£y, cells were scraped in ice-cold permea-
bilization bu¡er containing TPA, bFGF or their vehicle, pelleted and
permeabilized at 37‡C with 0.1% digitonin in the presence of [K-
32P]GTP. Incubation was stopped after 2 or 5 min with ice-cold lysis
bu¡er and Ras was immunoprecipitated from cell lysates with 1 Wg
anti-Ras antibody. Non-speci¢c (time 0) [K-32P]GTP binding was de-
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termined by adding lysis bu¡er before [K-32P]GTP and was sub-
tracted. Guanine nucleotides were then eluted from immunoprecipi-
tated Ras and radioactivity of the eluate counted by liquid scintilla-
tion.
3. Results
3.1. Ras requirement for ERK activation in cardiac cells
In a previous study we found that Ras activity was required
for activation of the GLUT1 promoter by the PKC activator
TPA [9]. In cardiac ¢broblasts, however, TPA could activate
the GLUT1 promoter independently of Ras. To extend these
observations, we used the hydroxymethylglutaryl CoA inhib-
itor lovastatin to inhibit Ras [13]. Inhibition of Ras farnesy-
lation and geranylgeranylation by lovastatin led to a dose-
dependent reduction of ERK1/2 activation by TPA in cardiac
myocytes, while lovastatin was without e¡ect in cardiac ¢bro-
blasts (Fig. 1A). To con¢rm that lovastatin actually inhibited
Ras function in ¢broblasts, we showed that activation of
ERK1/2 by bFGF was abolished by pretreatment with lova-
statin in cardiac myocytes as well as ¢broblasts (Fig. 1B). Fig.
1C shows quantitation of ERK1/2 activation in response to
TPA and bFGF in cardiac myocytes and ¢broblasts. Pretreat-
ment of the cells with 30 WM lovastatin markedly reduced
activation of ERK1/2 by bFGF in both cell types. In addition,
lovastatin reduced ERK1/2 activation by TPA in cardiac my-
ocytes, but was without e¡ect on TPA-activated ERK1/2 in
cardiac ¢broblasts. The residual ERK1/2 activation observed
in lovastatin-pretreated myocytes stimulated with TPA can
probably be attributed to contaminating ¢broblasts, since in
these cells ERK activation by TPA was more prominent than
in myocytes (39-fold vs. 23-fold).
3.2. Activation of Ras by TPA in cardiac myocytes
To explain the requirement for Ras for ERK1/2 activation
in response to TPA, we hypothesized that TPA was able to
induce GTP loading of Ras in cardiac myocytes. As shown in
Fig. 2A, TPA rapidly and potently activated Ras in cardiac
myocytes, but was unable to do so in ¢broblasts. To con¢rm
that ¢broblasts were responsive, we showed that bFGF and
Fig. 1. Ras is required for ERK activation by TPA only in cardiac
myocytes. A: Cardiac myocytes (2.5U105/3.5 cm dish) or cardiac ¢-
broblasts (con£uent in 3.5 cm dishes) were pretreated with varying
concentrations of lovastatin for 16 h. Cells were then stimulated
with TPA or its vehicle for 5 min, harvested in RIPA bu¡er and
doubly phosphorylated ERK1/2 and total ERK1/2 were detected by
Western Blot. B: Cardiac cells were pretreated with 30 WM lovasta-
tin or its vehicle for 16 h before stimulation with TPA or bFGF for
10 min. Doubly phosphorylated ERK1/2 and total ERK1/2 were de-
tected by Western blot. C: Quantitation of ERK1/2 activation. Car-
diac cells were pretreated with 30 WM lovastatin (black bars) or its
vehicle (white bars) for 16 h before stimulation with TPA or bFGF
for 10 min. Doubly phosphorylated ERK1/2 and total ERK1/2
were quantitated using the LumiImager system and the phos-
phoERK/total ERK ratio was determined. This ratio was arbitrarily
set to 1 in untreated cells. Results are mean þ S.E.M. of six (TPA)
or three (bFGF) experiments.
Fig. 2. TPA activates Ras in cardiac myocytes, not in cardiac ¢bro-
blasts. A: Cardiac myocytes (2U106/6 cm dish) or cardiac ¢bro-
blasts (con£uent in 10 cm dish) were treated for 10 min with either
TPA (1 WM), bFGF (25 ng/ml) or serum (FCS, 10%) as indicated.
Cells were then lysed and Ras-GTP was a⁄nity-precipitated using
GST-RBD and detected by Western blotting. Aliquots of total cell
lysate were run in parallel for detection of total Ras and doubly
phosphorylated ERK1/2. B: Time course of Ras activation by TPA
in cardiac myocytes. Cardiac myocytes were treated with 1 WM
TPA for the indicated time periods before Ras-GTP was quantitated
as described above. C: Reversal of Ras activation. Cardiac myo-
cytes were treated with either 0.1% ethanol (C) or 1 WM TPA. TPA
was removed (and replaced with 0.1% ethanol) after 10 min or 8 h
or left on the cells for 24 h. Ras-GTP was detected after 24 h, re-
gardless of the incubation time with TPA. D: Dose response of Ras
activation by TPA. Cardiac myocytes were treated with the indi-
cated concentrations of TPA for 10 min before Ras-GTP was quan-
titated as described above.
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FCS could activate Ras in these cells. In cardiac myocytes,
Ras activation by TPA occurred very rapidly (about 1 min)
and preceded activation of ERK1/2 (Fig. 2B). Both Ras GTP
loading and ERK1/2 dual phosphorylation were sustained for
at least 24 h in cardiac myocytes. Interestingly, Ras and
ERK1/2 activation persisted for 24 h even when TPA was
removed after 10 min or 8 h (Fig. 2C). Surprisingly, long-
term treatment of cardiac myocytes with TPA, with or with-
out removal, also resulted in down-regulation of total Ras.
Dose-response experiments showed that activation of Ras
in cardiac myocytes was clearly apparent with 10 nM TPA
and maximum activation was reached between 100 nM and
1 WM TPA (Fig. 2D). Activation of ERK1/2 by TPA followed
a similar dose-response curve, suggesting that activation of
ERK1/2 by TPA is actually mediated by Ras activation.
3.3. Ras activation by TPA is mediated by a PKC
Recently RasGRP, a guanine nucleotide release factor that
activates Ras in response to phorbol esters, has been described
and cloned from rat brain [14], thus providing an example of
how phorbol esters can directly stimulate a Ras GEF. Such a
mechanism of activation does not require PKC activity. To
assess whether Ras activation by TPA was mediated by a
PKC, we performed experiments with the selective PKC in-
hibitor chelerythrin [15]. As shown in Fig. 3, chelerythrin
totally suppressed activation of Ras in response to TPA. In
contrast, several broad-spectrum tyrosine kinase inhibitors
(lavendustin A, genistein and herbimycin A) failed to inhibit
activation of Ras by TPA. The tyrosine kinase inhibitors
were, however, able to reduce bFGF-induced activation of
ERK1/2. Consistently with Ras-GTP being una¡ected by ty-
rosine kinase inhibition, the tyrosine kinase inhibitors did not
reduce ERK activation induced by TPA, while the PKC in-
hibitor chelerythrin did.
3.4. TPA stimulates GRF activity in myocytes
The balance between GEF and GTPase activating protein
(GAP) activities determines the type of nucleotide (GTP vs.
GDP) bound to Ras. GEF activity in cardiac myocytes was
markedly stimulated by treatment of the cells with TPA. In
contrast, GEF activity in cardiac ¢broblasts was only mini-
mally increased by TPA treatment (data not shown); this
minor increment is probably caused by a small number of
contaminating myocytes in the ¢broblast preparation.
4. Discussion
The present study demonstrates that activation of the
ERK1/2 MAP kinase by phorbol esters is brought about by
di¡erent mechanisms in two distinct cardiac cell types in pri-
mary cultures. In cardiac myocytes, Ras is required for
ERK1/2 activation by the phorbol ester TPA; in addition
TPA induces GTP loading of Ras in this cell type. In contrast,
in cardiac ¢broblasts Ras activity is not required for activa-
tion of ERK1/2 by TPA and activation of PKC by TPA does
not a¡ect the activity of Ras.
Both the small G-protein Ras and proteins of the PKC
family play major roles in the control of cell growth, di¡er-
entiation and proliferation (see [15] for review). In cardiac
myocytes Ras is a key element of the signaling pathways lead-
ing to hypertrophy [1^4]. PKCs have also been involved in the
progression to hypertrophy in cardiac myocytes (reviewed in
[16]). Signaling downstream of Ras and PKC is usually
thought to converge onto activation of the kinases of the
Raf family, since Raf is recruited and activated by active
Ras on the one hand, and PKC can, at least in some cell
types, phosphorylate and activate Raf independently of Ras
activity [5].
In this study we have shown that phorbol esters activate
Ras in cardiac myocytes, thus demonstrating an additional
level of integration between signaling pathways involved in
cardiac myocyte hypertrophy. The rapid (1 min) appearance
of Ras-GTP in response to TPA treatment suggests that few
steps take place between activation of the phorbol ester target,
presumably a PKC, and activation of Ras. Based on such a
rapid kinetics for Ras activation, paracrine or autocrine ef-
fects can be ruled out. The phorbol ester’s direct target in this
Fig. 3. Ras activation by TPA is PKC-mediated. Cardiac myocytes
were pretreated for 30 min with either chelerythrin (5 WM), genistein
(50 WM), herbimycin A (1 WM), lavendustin A (10 WM) or the ve-
hicle (0.1% DMSO). The cells were then stimulated for 10P with
1 WM TPA (+), 0.1% ethanol (3) or 25 ng/ml bFGF (bFGF). Cells
were then lysed and Ras-GTP was a⁄nity-precipitated using GST-
RBD and detected by Western blotting. Doubly phosphorylated
ERK1/2 (pERK) was determined by Western blot. ND: not done.
Fig. 4. TPA stimulates GEF activity in cardiac myocytes. Cardiac
myocytes (2U106/6 cm dish) were scraped in permeabilization bu¡er
containing TPA or its vehicle, then permeabilized in the presence of
[K-32P]GTP for various times. The radiolabel on Ras was then de-
termined by immunoprecipitation. Results are shown as average þ
S.E.M. of four experiments.
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setting is most likely a PKC for the following reasons: (1) Ras
activation by TPA could be prevented by pretreatment with a
speci¢c PKC inhibitor, chelerythrin, and (2) the dose-response
curve for activation of Ras by TPA is compatible with the
EC50 reported for activation of members of the classic family
of PKC, i.e. 25^130 nM depending on the isozyme [17].
Ras output is tightly regulated by cycling between an active
GTP-bound conformation (Ras-GTP) and an inactive GDP-
bound state (Ras-GDP). The balance between Ras-GTP and
Ras-GDP is altered by modulation of the activity of GEFs
and GAPs. GEFs trigger the release of the guanine nucleotide
from Ras, thus enabling loading of GTP, which is much more
abundant than GDP in the cell cytoplasm. On the other hand,
GAPs enhance the intrinsic GTPase activity of Ras, thereby
terminating Ras signaling. In the present study we demon-
strated that activation of Ras in response to phorbol esters
occurred by stimulation of GEF activity (Fig. 4). Activation
of a GEF by phorbol esters has been previously demon-
strated. The Ras-activating guanine nucleotide exchange pro-
tein Vav is known to be activated by phorbol esters [18].
Expression of Vav is, however, limited to hematopoietic cells.
Recently, Ebinu and coworkers identi¢ed and cloned
RasGRP, a Ras guanine nucleotide release protein with cal-
cium and diacylglycerol binding motifs [14]. It was subse-
quently shown that activation of RasGRP by phorbol esters
requires binding of these compounds to a C1 domain very
similar to that found in PKC [19]. However, we do not believe
that such a mechanism is operative in cardiac myocytes for
the following reasons: (1) no expression of RasGRP could be
shown in heart tissue [14] and (2) activation of Ras by TPA
could be prevented by pretreatment with chelerythrin, a cata-
lytic domain inhibitor speci¢c for PKC [15].
Studies in pancreatic acinar cells have shown that activation
of PKC by phorbol esters led to Ras-GEF activation through
tyrosine phosphorylation of the adapter protein Shc [20,21].
However, in this study activation of Ras by TPA in cardiac
myocytes was resistant to inhibitors of tyrosine kinases, there-
fore suggesting a di¡erent mechanism, which remains un-
known. Also, the reason for the cardiac myocyte speci¢city
of the e¡ect remains to be investigated. Several hypotheses
can be envisaged: (1) a PKC isoform that is present in my-
ocytes but not in ¢broblasts is able to somehow activate
GEFs; (2) a myocyte-speci¢c GEF is a substrate for PKCs
or (3) a PKC substrate present in myocytes only mediates
GEF activation.
In conclusion, this work demonstrates that in cardiac my-
ocytes activation of PKC apparently results in activation of
Ras GEF independently of tyrosine kinases. This information
is of particular relevance for the understanding of the develop-
ment of cardiac hypertrophy, which is often associated with
stimuli that cause diacylglycerol production. This additional
level of integration between signaling pathways provides a
way by which PKC-activating agonists can stimulate signaling
pathways downstream of Ras that are more usually activated
in response to tyrosine kinases.
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